Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 130

Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2012', provides an overview of the Idiopathic Pulmonary Fibrosis therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis. 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Idiopathic Pulmonary Fibrosis.
- A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Idiopathic Pulmonary Fibrosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Idiopathic Pulmonary Fibrosis Therapeutic Products under Development, Key Players in Idiopathic Pulmonary Fibrosis Therapeutics, Idiopathic Pulmonary Fibrosis Pipeline Overview, Idiopathic Pulmonary Fibrosis Pipeline, Idiopathic Pulmonary Fibrosis Pipeline Assessment

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Idiopathic Pulmonary Fibrosis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Idiopathic Pulmonary Fibrosis 11
Idiopathic Pulmonary Fibrosis Therapeutics under Development by Companies 13
Idiopathic Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Idiopathic Pulmonary Fibrosis Therapeutics – Products under Development by Companies 22
Idiopathic Pulmonary Fibrosis Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Idiopathic Pulmonary Fibrosis Therapeutics Development 25
Bristol-Myers Squibb Company 25
Genzyme Corporation 26
Johnson & Johnson 27
Boehringer Ingelheim GmbH 28
Sanofi-Aventis 29
Gilead Sciences, Inc. 30
FibroGen, Inc. 31
Novartis AG 32
Actelion Ltd 33
InterMune, Inc. 34
Celgene Corporation 35
Geron Corporation 36
Oncothyreon Inc 37
Compugen Ltd. 38
LTT Bio-Pharma Co., Ltd. 39
axxonis Pharma AG 40
Auspex Pharmaceuticals 41
Promedior, Inc. 42
Mondobiotech Holding AG 43
Conatus Pharmaceuticals Inc. 44
GenKyoTex S.A. 45
Stromedix, Inc. 46
ImmuneRegen BioSciences, Inc. 47
ImmuneWorks, LLC 48
Pacific Therapeutics Ltd. 49
Idiopathic Pulmonary Fibrosis – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 57
GC1008 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
JNK CC-930 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Esbriet - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NBT-485 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
FG-3019 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Macitentan - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Homspera - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PC-SOD - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
CGEN-25009 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PX-866 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Vargatef - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PRM-151 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
STX-100 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
QAX-576 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
IW001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Prednisone + Azathioprine + N-Acetylcysteine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
GKT137831 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CNTO 888 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PTL-202 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Emricasan - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
GRN510 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Interferon Gamma - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Viagra + Cozaar - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Tracleer - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
GS 6624 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
BMS-986202 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Carbon Monoxide - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Inhaled rhPTX-2 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Plasma Exchange + Rituximab + Corticosteroids - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
SAR156597 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
DasKloster 1000-03 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
DasKloster 1001-01 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
nitric oxide - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Idiopathic Pulmonary Fibrosis Therapeutics – Drug Profile Updates 104
Idiopathic Pulmonary Fibrosis Therapeutics – Discontinued Products 119
Idiopathic Pulmonary Fibrosis Therapeutics - Dormant Products 120
Idiopathic Pulmonary Fibrosis – Product Development Milestones 122
Featured News & Press Releases 122
Jul 31, 2012: FibroGen’s FG-3019 Receives US Orphan Drug Designation For Treatment Of Patients With Idiopathic Pulmonary Fibrosis 122
Jul 12, 2012: Health Canada Endorses Important Safety Information On VOLIBRIS 122
Jul 10, 2012: Shionogi Files Lawsuit Against InterMune 123
Jun 28, 2012: Sweden's Dental And Pharmaceutical Benefits Agency Authorizes Reimbursement Of Esbriet 123
Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Volibris 123
May 03, 2012: FibroGen Announces Promising Preliminary Data From Phase II Study Of FG-3019 In Individuals With Idiopathic Pulmonary Fibrosis and Provides Program Update 124
Apr 10, 2012: Pacific Therapeutics Provides Update On Progress Of Clinical Development Of PTL-202 125
Mar 15, 2012: InerMune's Esbriet Receives Additional Benefit From German Federal Joint Committee 126
Mar 07, 2012: Promedior Receives US Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis 127
Jan 30, 2012: GNI Group Provides Update On F351 Patents 128
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 130
Disclaimer 130

List of Tables
Number of Products Under Development for Idiopathic Pulmonary Fibrosis, H2 2012 11
Products under Development for Idiopathic Pulmonary Fibrosis – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Development by Companies, H2 2012 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2012 24
Bristol-Myers Squibb Company, H2 2012 25
Genzyme Corporation, H2 2012 26
Johnson & Johnson, H2 2012 27
Boehringer Ingelheim GmbH, H2 2012 28
Sanofi-Aventis, H2 2012 29
Gilead Sciences, Inc., H2 2012 30
FibroGen, Inc., H2 2012 31
Novartis AG, H2 2012 32
Actelion Ltd, H2 2012 33
InterMune, Inc., H2 2012 34
Celgene Corporation, H2 2012 35
Geron Corporation, H2 2012 36
Oncothyreon Inc, H2 2012 37
Compugen Ltd., H2 2012 38
LTT Bio-Pharma Co., Ltd., H2 2012 39
axxonis Pharma AG, H2 2012 40
Auspex Pharmaceuticals, H2 2012 41
Promedior, Inc., H2 2012 42
Mondobiotech Holding AG, H2 2012 43
Conatus Pharmaceuticals Inc., H2 2012 44
GenKyoTex S.A., H2 2012 45
Stromedix, Inc., H2 2012 46
ImmuneRegen BioSciences, Inc., H2 2012 47
ImmuneWorks, LLC, H2 2012 48
Pacific Therapeutics Ltd., H2 2012 49
Assessment by Monotherapy Products, H2 2012 50
Assessment by Combination Products, H2 2012 51
Assessment by Stage and Route of Administration, H2 2012 53
Assessment by Stage and Molecule Type, H2 2012 56
Idiopathic Pulmonary Fibrosis Therapeutics – Drug Profile Updates 104
Idiopathic Pulmonary Fibrosis Therapeutics – Discontinued Products 119
Idiopathic Pulmonary Fibrosis Therapeutics – Dormant Products 120
Idiopathic Pulmonary Fibrosis Therapeutics – Dormant Products (Contd..1) 121

List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2012 11
Products under Development for Idiopathic Pulmonary Fibrosis – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 50
Assessment by Combination Products, H2 2012 51
Assessment by Route of Administration, H2 2012 52
Assessment by Stage and Route of Administration, H2 2012 53
Assessment by Molecule Type, H2 2012 54
Assessment by Stage and Molecule Type, H2 2012 55

Customers who bought this item also bought

• Global Idiopathic Pulmonary Fibrosis Drug Pipeline Capsule - 2012
• Global Cystic Fibrosis Drug Pipeline Capsule - 2012
• Niche Markets and Rare Diseases: Idiopathic Pulmonary Fibrosis
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?
• Bone Disorders – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013